Corrigendum to “Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer” [Canc. Lett. 438 (2018, Dec 1) 165–173]

Lin, Chang‐Ching; Lo, Miao‐Chia; Moody, Rebecca; Jiang, Hui; Harouaka, Ramdane; Stevers, Nicholas; Tinsley, Samantha L.; Gasparyan, Mari; Wicha, Max S.; Sun, Duxin

doi:10.1016/j.canlet.2020.01.013

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is downstream of apolipoprotein E2, which induces ERK1/2 phosphorylation to activate c-Myc and promotes the expression of cycle-related proteins involved in the malignant behavior of pancreatic cancer [27] . Inhibition of LRP8 inhibits the enrichment and proliferation of breast cancer stem cells in triple-negative breast cancer by weakening the Wnt/β-catenin signaling pathway [28] . In future studies, we will focus on the downstream signaling pathway of LRP8 to explore the effects of the miR-362-3p-LRP8 axis on the proliferation, invasion, and migration of ovarian cancer cells via the ERK1/2 or Wnt/β-catenin pathways.…”

Section: Discussionmentioning

confidence: 99%

miR-362-3p suppresses ovarian cancer by inhibiting LRP8

Yang²,

Wang³

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

Highlights MiR-362-3p inhibited cell viability and proliferation of ovarian cancer cells. MiR-362-3p inhibited cell migration and invasion of ovarian cancer cells. MiR-362-3p inhibited OV growth in vivo. LRP8 was a target of miR-362-3p. MiR-362-3p targeting LRP8 repressed cell viability and proliferation of ovarian cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%